Tumor cells often evoke specific immune responses that, however, fail to eliminate all the
tumor cells. The development of cancer immunotherapies is, therefore, mostly focused on
the generation of large numbers of activated anti-tumor effector cells by vaccination or
adoptive T cell transfer. These developments are built on an ever-extended list of identified
tumor-associated antigens and corresponding T cell epitopes, and a steady flow of reports
from proof-of-principle animal model experiments demonstrating cure from disease by …